More tools:
Markets
·
Screener
·
Research
·
Chat
First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX) Financial Statements
First Tracks Biotherapeutics, Inc. Ordinary Shares
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG020RF4R28
XNAS · usd
41.80
▲ 1.34 (3.31%)
As of 2026-09-08
1M
6M
1Y
Valuation
Market Cap
$1.5B
Enterprise Value
—
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
—
EBITDA
—
Diluted EPS (TTM)
—
EBITDA Margin
—
Net Debt
—
Trading Information
Previous Close
40.46
Day's Range
39.20 – 43.78
52-Week Range
14.72 – 49.91
Volume
525.5K
Avg Volume
603.0K
Share Statistics
Shares Outstanding
35.7M
Employees
—
Exchange
XNAS
Listed
2026-04-06
Share count as of August 7, 2026
View
Income Statement
Balance Sheet
Cash Flow
Key Metrics
Valuation
Comparable Companies
Notes & Facts
DCF Model
Earnings Calls
Guidance
Presentations
Detail
Standard
Detailed
Period
Annual
Quarterly
TTM
Loading Income Statement…
Key questions about First Tracks Biotherapeutics, Inc. Ordinary Shares (TRAX)
What is First Tracks Biotherapeutics, Inc. Ordinary Shares's Market Cap?
First Tracks Biotherapeutics, Inc. Ordinary Shares's Market Cap is $1.5B, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Subscribe
Income Statement
(in thousands of USD, except per-share data)
Source: Akyla.ai
Line Item
Jun 30, 2026
Mar 31, 2026
Jun 30, 2025
Mar 31, 2025
Operating expenses:
Research and development
25,644.0
—
General and administrative
9,293.0
—
Total operating expenses
34,937.0
—
Loss from operations
(34,937.0)
—
Other income (expense), net:
Interest income
1,564.0
—
Other expense, net
(1.0)
—
Total other income (expense), net
1,563.0
—
Net loss
(33,374.0)
(50,484.0)
Net loss per common share, Baisc
(0.95)
—
Net loss per common share, Diluted
(0.95)
—